An improvement in progression free survival was shown with trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2 positive metastatic breast cancer in the progression free survival interim analysis of the DESTINY Breast03 trial

Previous reports of the phase II DESTINY Breast01 trial conducted by Cristina Saura Manich MD PhD of Vall d Hebron Institute of Oncology Barcelona and colleagues showed that the HER2 targeting antibody drug conjugate fam trastuzumab deruxtecan nxki T DXd demonstrated durable responses as well as improved median progression free

In the single arm phase 2 DESTINY Breast01 trial trastuzumab deruxtecan showed robust activity in patients with HER2 positive metastatic breast cancer who were refractory or resistant to trastuzumab emtansine a population with scarce effective treatments

Trastuzumab deruxtecan versus treatment of physician 39 s choice

The DESTINY Breast01 study is a clinical study in participants with a type of breast cancer called HER2 positive breast cancer The participants in the study received a treatment called trastuzumab deruxtecan also known as T DXd

JNCCN 360 Breast Updated Survival Results From DESTINY

In updated results from the pivotal DESTINY Breast01 trial trastuzumab deruxtecan nxki T DXd demonstrated high rates of durable responses consistent with prior results with encouraging progression free survival and overall survival in patients with HER2 positive metastatic breast cancer

In this trial involving patients with HER2 low metastatic breast cancer trastuzumab deruxtecan resulted in significantly longer progression free and overall survival than the physician 39 s choice of chemotherapy

Destiny Breast 01 Trial

Trastuzumab deruxtecan versus trastuzumab emtansine in

Trastuzumab Deruxtecan in Previously Treated HER2 Positive

DESTINY Breast01 ENHERTU fam trastuzumab deruxtecan nxki

A single arm trial of 184 females with HER2 unresectable and or metastatic breast cancer who had received 2 prior anti HER2 therapies Patients received ENHERTU 5 4 mg kg IV once every 3 weeks until disease progression or unacceptable toxicity

Trastuzumab deruxtecan in previously treated HER2 positive

Miami Breast Cancer Conference Updated DESTINY Breast01

Background In the single arm phase 2 DESTINY Breast01 trial trastuzumab deruxtecan showed robust activity in patients with HER2 positive metastatic breast cancer who were refractory or resistant to trastuzumab emtansine a population with scarce effective treatments

Trastuzumab deruxtecan versus treatment of physician 39 s choice

Trastuzumab deruxtecan in previously treated patients with

Videos for Destiny Breast 01 Trial

Trastuzumab deruxtecan T DXd vs trastuzumab emtansine T

In the DESTINY Breast01 trial the occurrence of interstitial lung disease or pneumonitis was identified as an important risk associated with trastuzumab deruxtecan

DESTINY Clinical Trials for Metastatic Breast Cancer

In this two part open label single group multicenter phase 2 study we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2 positive meta static breast cancer who

The phase II DESTINY Breast01 trial NCT03248492 assessed trastuzumab deruxtecan T DXd 5 4 mg kg in patients with human epidermal growth factor receptor 2 HER2 positive metastatic breast cancer mBC with promising efficacy results

In the pivotal DESTINY Breast01 trial efficacy of T DXd in HER2 positive metastatic breast cancer mBC was demonstrated with an objective response rate ORR of 60 9 and median progression free survival mPFS of 16 4 months

In this two part open label single group multicenter phase 2 study we evaluated trastuzumab deruxtecan in adults with pathologically documented HER2 positive metastatic breast cancer who had

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for

The DESTINY Breast04 trial established HER2 low tumors as a targetable clinical entity with patients deriving a clinical benefit with trastuzumab deruxtecan after receipt of chemotherapy 17

Trastuzumab Deruxtecan in Previously Treated HER2 Positive

Background DESTINY Breast DB 01 02 and 03 evaluated T DXd in pts with HER2 mBC who received 1 prior line of therapy These studies showed confirmed objective response rates by independent central review ICR blinded for DB 02 and 03 of 62 70 and 79 and complete response CR rates of 7 14 and 21 respectively with T DXd

Trastuzumab deruxtecan in previously treated patients with

279P Trastuzumab deruxtecan T DXd in patients with HER2

In this trial involving patients with HER2 low metastatic breast cancer trastuzumab deruxtecan resulted in significantly longer progression free and overall survival than the physician s

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic

Trastuzumab Deruxtecan in Previously Treated HER2 Low

Find information on Phase 3 fam trastuzumab deruxtecan DS 8201 trials for eligible patients with metastatic breast cancer

Destiny Breast 01 Trial

Pooled analysis by best confirmed response to trastuzumab

Background Primary analysis of the multicenter open label single arm phase II DESTINY Breast01 trial median follow up 11 1 months demonstrated durable antitumor activity with trastuzumab deruxtecan T DXd in patients with human epidermal growth factor receptor 2 HER2 positive metastatic breast cancer mBC previously treated with

Background DESTINY Breast03 NCT03529110 a randomized multicenter open label phase 3 study assessed the efficacy and safety of T DXd vs T DM1 in pts with HER2 mBC treated with 1 prior anti HER2 regimen Median m overall survival OS was not reached in either arm at the prior data cutoff DCO Jul 25 2022

Trastuzumab Deruxtecan in Previously Treated HER2 Low

Trastuzumab deruxtecan for HER2 positive metastatic breast

DESTINY Breast01 NCT03248492 is an open label international multicenter phase 2 study of T DXd in patients with HER2 positive MBC it supported regulatory approval globally Data from prior data cutoffs primary August 1 2019 initial update June 8 2020 showed that patients receiving T DXd had durable responses